Literature DB >> 17064931

Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature.

M H Nieuwenhuis1, H F A Vasen.   

Abstract

Mutations in the adenomatous polyposis coli (APC) gene cause familial adenomatous polyposis (FAP). Disease severity and the presence of extracolonic manifestations seem to be correlated with the location of the mutation on the APC gene. In this review, large studies describing genotype-phenotype correlations in FAP were evaluated and categorized. Attenuated FAP (AFAP, <100 colorectal adenomas) is correlated with mutations before codon 157, after codon 1595 and in the alternatively spliced region of exon 9. Severe polyposis (>1000 adenomas) is found in patients with mutations between codons 1250 and 1464. Mutations in the remainder of the APC gene cause an intermediate phenotype (hundred to thousands of adenomas). Congenital hypertrophy of the retinal pigment epithelium (CHRPE) and desmoid tumours are associated with mutations between codons 311 and 1444 and after codon 1444, respectively. No consistent correlations were found for upper gastrointestinal tumours. Genotype-phenotype correlations in FAP will be useful in decisions concerning screening and surgical management of FAP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064931     DOI: 10.1016/j.critrevonc.2006.07.004

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  127 in total

Review 1.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

Review 2.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

3.  Detection of novel mitochondrial mutations in cytochrome C oxidase subunit 1 (COX1) in patients with familial adenomatous polyposis (FAP).

Authors:  E Afkhami; M M Heidari; M Khatami; F Ghadamyari; S Dianatpour
Journal:  Clin Transl Oncol       Date:  2019-09-24       Impact factor: 3.405

Review 4.  The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes.

Authors:  Stefan Aretz
Journal:  Dtsch Arztebl Int       Date:  2010-03-12       Impact factor: 5.594

Review 5.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

6.  Germline APC Mutation and Familial Barrett Esophagus: Causal or Coincidence?

Authors:  John Fang; Kory Jasperson
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

7.  Prevalence of Synchronous Oligopolyposis in Incident Colorectal Cancer: A Population-Based Study.

Authors:  Juan M Marqués-Lespier; Marievelisse Soto-Salgado; María González-Pons; Vanessa Méndez; Katerina Freyre; Carlos Beltrán; Luis R Pericchi; Marcia Cruz-Correa
Journal:  P R Health Sci J       Date:  2018-03       Impact factor: 0.705

Review 8.  Understanding phenotypic variation in rodent models with germline Apc mutations.

Authors:  Maged Zeineldin; Kristi L Neufeld
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

9.  How does inflammation drive mutagenesis in colorectal cancer?

Authors:  Chia Wei Hsu; Mark L Sowers; Willie Hsu; Eduardo Eyzaguirre; Suimin Qiu; Celia Chao; Charles P Mouton; Yuri Fofanov; Pomila Singh; Lawrence C Sowers
Journal:  Trends Cancer Res       Date:  2017

10.  APC mutation spectrum of Norwegian familial adenomatous polyposis families: high ratio of novel mutations.

Authors:  Per Arne Andresen; Ketil Heimdal; Kristin Aaberg; Katrine Eklo; Kristin Eklo; Sarah Ariansen; Alexandra Silye; Olav Fausa; Lars Aabakken; Stefan Aretz; Tor J Eide; Tobias Gedde-Dahl
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.